Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 20/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1382866 | 0.90 | HPGD (0.54) | HPGDALDH1A1NPC1GLARAB9A | |
| SCHEMBL1378737 | 0.90 | HPGD (0.53) | HPGDALDH1A1NPC1GLARAB9A | |
| SCHEMBL1379013 | 0.87 | HPGD (0.61) | HPGDALDH1A1NPC1GLARAB9A | |
| SCHEMBL1378738 | 0.86 | HPGD (0.52) | HPGDALDH1A1NPC1GLARAB9A | |
| SCHEMBL1381836 | 0.84 | HPGD (0.54) | HPGDALDH1A1NPC1GLARAB9A | |
| SCHEMBL4485682 | 0.83 | HPGD (0.53) | HPGDALDH1A1NPC1RAB9A | |
| SCHEMBL1377978 | 0.81 | MAPK1 (0.52) | HPGDALDH1A1NPC1SMN1; SMN2 | |
| SCHEMBL1379340 | 0.81 | RIPK1 (0.54) | HPGDNPC1SMN1; SMN2 | |
| SCHEMBL1379505 | 0.79 | HPGD (0.52) | HPGDALDH1A1NPC1RAB9A | |
| SCHEMBL1381540 | 0.78 | ALOX5 (0.51) | HPGDNPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4769720-B2 | — | — | 2011-09-07 | — | — | JP | claimed |
| US-20060189629-A1 | N-substituted benzimidazolyl c-Kit inhibitors | OSI PHARMACEUTICALS, INC. | 2006-08-24 | — | — | US | claimed |
| EP-1664021-A1 | N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS | OSI Pharmaceuticals, Inc. (US) | 2006-06-07 | — | — | EP | claimed |
| WO-2005021531-A1 | N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2005-03-10 | — | — | WO | claimed |
| US-7521448-B2 | N-substituted benzimidazolyl c-Kit inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2009-04-21 | — | — | US | disclosed |
| US-20060189629-A1 | N-substituted benzimidazolyl c-Kit inhibitors | OSI PHARMACEUTICALS, INC. | 2006-08-24 | — | — | US | disclosed |
| EP-1664021-A1 | N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS | OSI Pharmaceuticals, Inc. (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005021531-A1 | N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189629-A1 | N-substituted benzimidazolyl c-Kit inhibitors | KIT, CHUK, TNNI3K | HPGD 1154/4885ALDH1A1 430/4885NPC1 1706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.